Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Jul 14;6(1):267.
doi: 10.1038/s41392-021-00689-y.

Real-world evidence for improved outcomes with histamine antagonists and aspirin in 22,560 COVID-19 patients

Cameron Mura #  1 , Saskia Preissner #  2 , Susanne Nahles  3 , Max Heiland  3 , Philip E Bourne  4 , Robert Preissner  5
Affiliations
Comment

Real-world evidence for improved outcomes with histamine antagonists and aspirin in 22,560 COVID-19 patients

Cameron Mura et al. Signal Transduct Target Ther. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Kaplan–Meier survival curves are shown for COVID-19 patients with (blue) or without (red) the dual combination treatment of famotidine and aspirin; the time-evolution of survival probabilities is given in terms of number of days after the index event (a positive COVID-19 diagnosis)
See this image and copyright information in PMC

Comment on

  • Histamine receptors and COVID-19.
    Ennis M, Tiligada K. Ennis M, et al. Inflamm Res. 2021 Jan;70(1):67-75. doi: 10.1007/s00011-020-01422-1. Epub 2020 Nov 18. Inflamm Res. 2021. PMID: 33206207 Free PMC article.

References

    1. Ennis M, Tiligada K. Histamine receptors and COVID-19. Inflamm. Res. 2021;70:67–75. doi: 10.1007/s00011-020-01422-1. - DOI - PMC - PubMed
    1. Freedberg DE, et al. Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: a propensity score matched retrospective cohort study. Gastroenterology. 2020;159:1129–1131 e1123. doi: 10.1053/j.gastro.2020.05.053. - DOI - PMC - PubMed
    1. Mura, C., Preissner, S., Preissner, R. & Bourne, P. E. A birds-eye (Re)view of acid-suppression drugs, COVID-19, and the highly variable literature. Preprint at https://arxiv.org/abs/2104.12003 (2021). - PMC - PubMed
    1. Hogan II RB, et al. Dual-histamine receptor blockade with cetirizine-famotidine reduces pulmonary symptoms in COVID-19 patients. Pulm. Pharm. Ther. 2020;63:101942. doi: 10.1016/j.pupt.2020.101942. - DOI - PMC - PubMed
    1. Loucera C, et al. Drug repurposing for COVID-19 using machine learning and mechanistic models of signal transduction circuits related to SARS-CoV-2 infection. Signal Transduct. Target Ther. 2020;5:290. doi: 10.1038/s41392-020-00417-y. - DOI - PMC - PubMed